Susquehanna International Group
MGX icon

Susquehanna International Group’s Metagenomi Therapeutics MGX Stock Holding History

Susquehanna International Group’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-72,587
Closed -$107K – 14115
2025
Q2 		$107K Buy
72,587
+39,337
+118% +$61.6K ﹤0.01% 11753
2025
Q1 		$45.2K Buy
33,250
+21,438
+181% +$51.1K ﹤0.01% 11897
2024
Q4 		$42.6K Buy
+11,812
New +$28.5K ﹤0.01% 11740

Other funds holding MGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SVGI
Sozo Ventures GP II Redwood City, California $1.33M AUM 9.22% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Susquehanna International Group's MGX Position: Q3 2025 in Review

Susquehanna International Group sold out of Metagenomi Therapeutics (MGX) in Q3 2025, closing a stake of 72,587 shares — an estimated $107K sold.

Susquehanna International Group first reported a position in MGX in Q4 2024 and held it in 3 quarters. The position peaked at $107K in Q2 2025. 58 funds tracked by Wall St. Rank hold MGX as of Q3 2025.

  • Susquehanna International Group reported no remaining Metagenomi Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Susquehanna International Group sold 72,587 Metagenomi Therapeutics shares in Q3 2025, an estimated $107K.
  • Susquehanna International Group first reported a position in Metagenomi Therapeutics in Q4 2024 and held it in 3 quarters.
  • Susquehanna International Group's Metagenomi Therapeutics position peaked at $107K in Q2 2025.
  • 58 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q3 2025.

Based on Susquehanna International Group's 13F filing for Q3 2025, filed 14 Nov 2025.